Peptide Therapeutics Market by Route of Administration (Parenteral, Oral, and Others), by Type (Innovative and Generic), by Type of Manufacturers (In-house and Outsourced), by Type of Molecule (Vasopressin, Somatostatin, Calcitonin, Immunopeptide, Natriuretic, and Others), by Technology (Liquid Phase, Solid Phase, and Hybrid Phase), and by Application (Cancer, Cardiovascular Disease, Metabolic Disease, Respiratory Disease, Infectious Disease, and Others): Global Industry Perspective, Comprehensive Analysis and Forecast, 2017 – 2024

Description

The report covers forecast and analysis for the peptide therapeutics market on a global and regional level. The study provides historical data from 2015 to 2017 along with a forecast from 2018 to 2024 based on revenue (USD Billion). The study includes drivers and restraints for the peptide therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the peptide therapeutics market on a global level.

In order to give the users of this report a comprehensive view of the peptide therapeutics market, we have included a competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein all segments are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new service type launch, agreements, partnerships, collaborations & joint ventures, research & development, service type, and regional expansion of major participants involved in the market.

The study provides a decisive view on the peptide therapeutics market by segmenting it on the route of administration, type, type of manufacturers, type of molecule, technology, application, and region. All the segments have been analyzed based on present and future trends and the market is estimated from 2018 to 2024. The regional segmentation includes the current and forecast demand for North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa with its further categorization into major countries including the U.S., the UK, Germany, France, China, Japan, India, Brazil, etc. This segmentation includes demand for peptide therapeutics market based on all segments in all the regions and countries.

The key players in the global peptide therapeutics market are Amgen Inc., Pfizer Inc., Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Lonza Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Sanofi, AstraZeneca PLC, and Novartis AG.

This report segments the global peptide therapeutics market as follows:

Global Peptide Therapeutics Market: Route of Administration Segment Analysis

• Parenteral
• Oral
• Others

Global Peptide Therapeutics Market: Type Segment Analysis

• Innovative
• Generic

Global Peptide Therapeutics Market: Type of Manufacturers Segment Analysis

• In-house
• Outsourced

Global Peptide Therapeutics Market: Type of Molecule Segment Analysis

• Vasopressin
• Somatostatin
• Calcitonin
• Immunopeptide
• Natriuretic
• Others

Global Peptide Therapeutics Market: Technology Segment Analysis

• Solid Phase
• Liquid Phase
• Hybrid Phase

Global Peptide Therapeutics Market: Application Segment Analysis

• Cancer
• Cardiovascular Disease
• Metabolic Disease
• Respiratory Disease
• Infectious Disease
• Others

Global Peptide Therapeutics Market: Regional Segment Analysis

• North America
  • The U.S.
• Europe
  • UK
  • France
  • Germany
• Asia Pacific
  • China
  • Japan
  • India
• Latin America
  • Brazil
• Middle East and Africa

Table Of Content

• Chapter 1. Introduction
  • 1.1. Report description and scope
  • 1.2. Research scope
  • 1.3. Research methodology
    • 1.3.1. Market research process
    • 1.3.2. Market research methodology
•  
• Chapter 2. Executive Summary
  • 2.1. Global peptide therapeutics market, 2015 - 2024 (USD Billion)
  • 2.2. Global peptide therapeutics market: Snapshot
•  
• Chapter 3. Peptide Therapeutics Market - Dynamics
  • 3.1. Introduction
  • 3.2. Market drivers
    • 3.2.1. Global peptide therapeutics market drivers: Impact analysis
    • 3.2.2. Advances in peptide synthesis technology
    • 3.2.3. Presence of strong product pipeline portfolio
    • 3.2.4. Increasing prevalence of cancer
    • 3.2.5. Rise in occurrence of metabolic disorders
  • 3.3. Market Restraints
    • 3.3.1. Global peptide therapeutics market restraints: Impact analysis
    • 3.3.2. Stringent regulatory compliances
    • 3.3.3. Intense market competition
  • 3.4. Opportunities
    • 3.4.1. Innovation of new products
    • 3.4.2. Increase in research in emerging economies
  • 3.5. Porter's five forces analysis
    • 3.5.1. Bargaining power of suppliers
    • 3.5.2. Bargaining power of buyers
    • 3.5.3. Threat from new entrants
    • 3.5.4. Threat from new substitutes
    • 3.5.5. Degree of competition
  • 3.6. Market attractiveness analysis
    • 3.6.1. Market attractiveness analysis, by route of administration segment
    • 3.6.2. Market attractiveness analysis, by type segment
    • 3.6.3. Market attractiveness analysis, by type of manufacturers segment
    • 3.6.4. Market attractiveness analysis, by type of molecule segment
    • 3.6.5. Market attractiveness analysis, by technology segment
    • 3.6.6. Market attractiveness analysis, by application segment
    • 3.6.7. Market attractiveness analysis, by regional segment
•  
• Chapter 4. Global Peptide Therapeutics Market - Competitive Landscape
  • 4.1. Company market share analysis
    • 4.1.1. Global peptide therapeutics market: company market share, 2017
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New material launch
    • 4.2.3. Agreements, partnerships, collaborations and joint ventures
    • 4.2.4. Research and development and regional expansion
•  
• Chapter 5. Global Peptide Therapeutics Market -Route of Administration Segment Analysis
  • 5.1. Global peptide therapeutics market: Route of Administration overview
    • 5.1.1. Global peptide therapeutics market revenue share, by route of administration, 2017 and 2024
  • 5.2. Parenteral
    • 5.2.1. Global peptide therapeutics market for parenteral, 2015 - 2024 (USD Billion)
  • 5.3. Oral
    • 5.3.1. Global peptide therapeutics market for oral, 2015 - 2024 (USD Billion)
  • 5.4. Others
    • 5.4.1. Global peptide therapeutics market for others, 2015 - 2024 (USD Billion)
•  
• Chapter 6. Global Peptide Therapeutics Market -Type Segment Analysis
  • 6.1. Global peptide therapeutics market: Type overview
    • 6.1.1. Global peptide therapeutics market revenue share, by type, 2017 and 2024
  • 6.2. Innovative
    • 6.2.1. Global peptide therapeutics market for bare metal stents, 2015 - 2024 (USD Billion)
  • 6.3. Generic
    • 6.3.1. Global peptide therapeutics market for generic, 2015 - 2024 (USD Billion)
•  
• Chapter 7. Global Peptide Therapeutics Market -Type of Manufacturers Segment Analysis
  • 7.1. Global peptide therapeutics market: type of manufacturers overview
    • 7.1.1. Global peptide therapeutics market revenue share, by type of manufacturers, 2017 and 2024
  • 7.2. In-house
    • 7.2.1. Global peptide therapeutics market for in-house, 2015 - 2024 (USD Billion)
  • 7.3. Outsourced
    • 7.3.1. Global peptide therapeutics market for outsourced, 2015 - 2024 (USD Billion)
•  
• Chapter 8. Global Peptide Therapeutics Market -Type of Molecule Segment Analysis
  • 8.1. Global peptide therapeutics market: Type of molecule overview
    • 8.1.1. Global peptide therapeutics market revenue share, by type of molecule, 2017 and 2024
  • 8.2. Vasopressin
    • 8.2.1. Global peptide therapeutics market for vasopressin, 2015 - 2024 (USD Billion)
  • 8.3. Somatostatin
    • 8.3.1. Global peptide therapeutics market for somatostatin, 2015 - 2024 (USD Billion)
  • 8.4. Calcitonin
    • 8.4.1. Global peptide therapeutics market for calcitonin, 2015 - 2024 (USD Billion)
  • 8.5. Immunopeptide
    • 8.5.1. Global peptide therapeutics market for immunopeptide, 2015 - 2024 (USD Billion)
  • 8.6. Natriuretic
    • 8.6.1. Global peptide therapeutics market for natriuretic, 2015 - 2024 (USD Billion)
  • 8.7. Others
    • 8.7.1. Global peptide therapeutics market for others, 2015 - 2024 (USD Billion)
•  
• Chapter 9. Global Peptide Therapeutics Market - Technology Segment Analysis
  • 9.1. Global peptide therapeutics market: End-use overview
    • 9.1.1. Global peptide therapeutics market revenue share, by technology, 2017 and 2024
  • 9.2. Solid Phase
    • 9.2.1. Global peptide therapeutics market for solid phase, 2015 - 2024 (USD Billion)
  • 9.3. Liquid Phase
    • 9.3.1. Global peptide therapeutics market for liquid phase, 2015 - 2024 (USD Billion)
  • 9.4. Hybrid Phase
    • 9.4.1. Global peptide therapeutics market for hybrid phase, 2015 - 2024 (USD Billion)
•  
• Chapter 10. Global Peptide Therapeutics Market - Technology Segment Analysis
  • 10.1. Global peptide therapeutics market: Technology overview
    • 10.1.1. Global peptide therapeutics market revenue share, by technology, 2017 and 2024
  • 10.2. Cancer
    • 10.2.1. Global peptide therapeutics market for cancer, 2015 - 2024 (USD Billion)
  • 10.3. Cardiovascular Disease
    • 10.3.1. Global peptide therapeutics market for cardiovascular disease, 2015 - 2024 (USD Billion)
  • 10.4. Metabolic Disease
    • 10.4.1. Global peptide therapeutics market for metabolic disease, 2015 - 2024 (USD Billion)
  • 10.5. Respiratory Disease
    • 10.5.1. Global peptide therapeutics market for respiratory disease, 2015 - 2024 (USD Billion)
  • 10.6. Infectious Disease
    • 10.6.1. Global peptide therapeutics market for infectious disease, 2015 - 2024 (USD Billion)
  • 10.7. Others
    • 10.7.1. Global peptide therapeutics market for others, 2015 - 2024 (USD Billion)
•  
• Chapter 11. Global Peptide Therapeutics Market - Regional Segment Analysis
  • 11.1. Global peptide therapeutics market: Regional overview
    • 11.1.1. Global peptide therapeutics market revenue share, by region, 2017 and 2024
  • 11.2. North America
    • 11.2.1. North America peptide therapeutics market, 2015 - 2024 (USD Billion)
    • 11.2.2. North America peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
    • 11.2.3. North America peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
    • 11.2.4. North America peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
    • 11.2.5. North America peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
    • 11.2.6. North America peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
    • 11.2.7. North America peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.2.8. The U.S.
      • 11.2.8.1. The U.S. peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.2.8.2. The U.S. peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.2.8.3. The U.S. peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.2.8.4. The U.S. peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.2.8.5. The U.S. peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.2.8.6. The U.S. peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.2.9. Canada
      • 11.2.9.1. Canada peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.2.9.2. Canada peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.2.9.3. Canada peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.2.9.4. Canada peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.2.9.5. Canada peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.2.9.6. Canada peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
  • 11.3. Europe
    • 11.3.1. Europe peptide therapeutics market, 2015 - 2024 (USD Billion)
    • 11.3.2. Europe peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
    • 11.3.3. Europe peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
    • 11.3.4. Europe peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
    • 11.3.5. Europe peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
    • 11.3.6. Europe peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
    • 11.3.7. Europe peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.3.8. UK
      • 11.3.8.1. UK peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.3.8.2. UK peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.3.8.3. UK peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.3.8.4. UK peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.3.8.5. UK peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.3.8.6. UK peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.3.9. Germany
      • 11.3.9.1. Germany peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.3.9.2. Germany peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.3.9.3. Germany peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.3.9.4. Germany peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.3.9.5. Germany peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.3.9.6. Germany peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.3.10. France
      • 11.3.10.1. France peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.3.10.2. France peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.3.10.3. France peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.3.10.4. France peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.3.10.5. France peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.3.10.6. France peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.3.11. Rest of Europe
      • 11.3.11.1. Rest of Europe peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.3.11.2. Rest of Europe peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.3.11.3. Rest of Europe peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.3.11.4. Rest of Europe peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.3.11.5. Rest of Europe peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.3.11.6. Rest of Europe peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
  • 11.4. Asia Pacific
    • 11.4.1. Asia Pacific peptide therapeutics market, 2015 - 2024 (USD Billion)
    • 11.4.2. Asia Pacific peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
    • 11.4.3. Asia Pacific peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
    • 11.4.4. Asia Pacific peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
    • 11.4.5. Asia Pacific peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
    • 11.4.6. Asia Pacific peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
    • 11.4.7. Asia Pacific peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.4.8. China
      • 11.4.8.1. China peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.4.8.2. China peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.4.8.3. China peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.4.8.4. China peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.4.8.5. China peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.4.8.6. China peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.4.9. Japan
      • 11.4.9.1. Japan peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.4.9.2. Japan peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.4.9.3. Japan peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.4.9.4. Japan peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.4.9.5. Japan peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.4.9.6. Japan peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.4.10. India
      • 11.4.10.1. India peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.4.10.2. India peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.4.10.3. India peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.4.10.4. India peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.4.10.5. India peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.4.10.6. India peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.4.11. Rest of Asia Pacific
      • 11.4.11.1. Rest of Asia Pacific peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.4.11.2. Rest of Asia Pacific peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.4.11.3. Rest of Asia Pacific peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.4.11.4. Rest of Asia Pacific peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.4.11.5. Rest of Asia Pacific peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.4.11.6. Rest of Asia Pacific peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
  • 11.5. Latin America
    • 11.5.1. Latin America peptide therapeutics market, 2015 - 2024 (USD Billion)
    • 11.5.2. Latin America peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
    • 11.5.3. Latin America peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
    • 11.5.4. Latin America peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
    • 11.5.5. Latin America peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
    • 11.5.6. Latin America peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
    • 11.5.7. Latin America peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.5.8. Brazil
      • 11.5.8.1. Brazil peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.5.8.2. Brazil peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.5.8.3. Brazil peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.5.8.4. Brazil peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.5.8.5. Brazil peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.5.8.6. Brazil peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
    • 11.5.9. Rest of Latin America
      • 11.5.9.1. Rest of Latin America peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
      • 11.5.9.2. Rest of Latin America peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
      • 11.5.9.3. Rest of Latin America peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
      • 11.5.9.4. Rest of Latin America peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
      • 11.5.9.5. Rest of Latin America peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
      • 11.5.9.6. Rest of Latin America peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
  • 11.6. The Middle East and Africa
    • 11.6.1. The Middle East and Africa peptide therapeutics market, 2015 - 2024 (USD Billion)
    • 11.6.2. The Middle East and Africa peptide therapeutics market revenue, by route of administration, 2015 - 2024 (USD Billion)
    • 11.6.3. The Middle East and Africa peptide therapeutics market revenue, by type, 2015 - 2024 (USD Billion)
    • 11.6.4. The Middle East and Africa peptide therapeutics market revenue, by type of manufacturers, 2015 - 2024 (USD Billion)
    • 11.6.5. The Middle East and Africa peptide therapeutics market revenue, by type of molecule, 2015 - 2024 (USD Billion)
    • 11.6.6. The Middle East and Africa peptide therapeutics market revenue, by technology, 2015 - 2024 (USD Billion)
    • 11.6.7. The Middle East and Africa peptide therapeutics market revenue, by application, 2015 - 2024 (USD Billion)
•  
• Chapter 12. Company Profile
  • 12.1. Amgen Inc.
    • 12.1.1. Overview
    • 12.1.2. Financials
    • 12.1.3. Product Portfolio
    • 12.1.4. Business Strategy
    • 12.1.5. Recent Developments
  • 12.2. Pfizer Inc.
    • 12.2.1. Overview
    • 12.2.2. Financials
    • 12.2.3. Product Portfolio
    • 12.2.4. Business Strategy
    • 12.2.5. Recent Developments
  • 12.3. Eli Lilly and Company
    • 12.3.1. Overview
    • 12.3.2. Financials
    • 12.3.3. Product Portfolio
    • 12.3.4. Business Strategy
    • 12.3.5. Recent Developments
  • 12.4. Teva Pharmaceuticals Industries Ltd.
    • 12.4.1. Overview
    • 12.4.2. Financials
    • 12.4.3. Product Portfolio
    • 12.4.4. Business Strategy
    • 12.4.5. Recent Developments
  • 12.5. Lonza Inc.
    • 12.5.1. Overview
    • 12.5.2. Financials
    • 12.5.3. Product Portfolio
    • 12.5.4. Business Strategy
    • 12.5.5. Recent Developments
  • 12.6. Takeda Pharmaceutical Company Limited
    • 12.6.1. Overview
    • 12.6.2. Financials
    • 12.6.3. Product Portfolio
    • 12.6.4. Business Strategy
    • 12.6.5. Recent Developments
  • 12.7. Bristol-Myers Squibb
    • 12.7.1. Overview
    • 12.7.2. Financials
    • 12.7.3. Product Portfolio
    • 12.7.4. Business Strategy
    • 12.7.5. Recent Developments
  • 12.8. Sanofi
    • 12.8.1. Overview
    • 12.8.2. Financials
    • 12.8.3. Product Portfolio
    • 12.8.4. Business Strategy
    • 12.8.5. Recent Developments
  • 12.9. AstraZeneca PLC
    • 12.9.1. Overview
    • 12.9.2. Financials
    • 12.9.3. Product Portfolio
    • 12.9.4. Business Strategy
    • 12.9.5. Recent Developments
  • 12.10. Novartis AG
    • 12.10.1. Overview
    • 12.10.2. Financials
    • 12.10.3. Product Portfolio
    • 12.10.4. Business Strategy
    • 12.10.5. Recent Developments 

Methodology

Free Analysis

Peptide therapeutics is a type of treatment in which the peptides are used to activate the functions of the cells against the diseases. The peptide is a signaling molecule which binds to the receptors on the cells to activate the cell to secrete molecules. 

According to WHO (World Health Organization), the population aged above 65 years is expected to increase to 2 billion by 2050. Mainly the population above 65 years suffers from various chronic diseases. This increases the demand for peptide therapy due to an increase in the awareness about the novel and effective drugs. Also, the massive investments made by the government and companies for research & development activities across pharmaceutical, biotechnological, and biopharmaceutical industries is likely to propel the growth of the peptide research, which, in turn, will further fuel the peptide therapeutics market trends. The development of advanced technologies and product in peptide therapy and rise in people suffering from metabolic, cardiovascular, respiratory, and other diseases are some of the factors contributing to the growth of the peptide therapeutics market.

The Peptide therapeutics market is segmented on the administration route, type, type of manufacturers, type of molecule, technology, and application. Based on the route of administration, the market is divided into parenteral, oral, and others. On the basis of type, the peptide therapeutics market is further segmented into generic and innovative. Type of manufacturers includes in-house and outsourced segment. Based on the type of molecule, the market for peptide therapeutics is segmented into natriuretic, somatostatin, vasopressin, immunopeptide, calcitonin, and others. On the basis of technology, the market for peptide therapeutics is further segmented into the liquid phase, hybrid phase, and solid phase. The application segment includes cancer, metabolic disease, cardiovascular disease, infectious disease, respiratory disease, and others.

North America is anticipated to lead the market in the upcoming period due to the advancement in the use of peptide therapeutics as a drug to treat cancer and the rising incidences of chronic diseases and cancer. Asia Pacific peptide therapeutics market is expected to show the highest growth, owing to the presence of established API providers and generic industry with the stable economy rate in some countries of Asia Pacific. Also, the increased investment in biotechnological & pharmaceutical industry by government and companies are driving the growth of the peptide therapeutics market.

The main players in the global peptide therapeutics market are Amgen Inc., Pfizer Inc., Eli Lilly and Company, Teva Pharmaceuticals Industries Ltd., Lonza Inc., Takeda Pharmaceutical Company Limited, Bristol-Myers Squibb, Sanofi, AstraZeneca PLC, and Novartis AG. The main companies are focusing on increasing mergers, collaborations, and acquisitions. For instance, Cancer Research UK entered an agreement with Bicycle Therapeutics for funding the clinical trial of Phase Ia and Ib which can be used for the treatment of solid tumors.